Last update March 19, 2020

Carbidopa

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

A peripheral inhibitor of the enzyme dopa-decarboxylase which transforms levodopa into dopamine.
Its only medical use is to associate it with levodopa in the treatment of Parkinson's disease in order to block the peripheral effects of levodopa by becoming dopamine (nausea, vomiting, arrhythmias) and allowing more levodopa to reach the brain and levodopa can be given at a lower dose.
Carbidopa does not cross the blood-brain barrier, so it has no effects at the level of the central nervous system.
Oral administration 3 to 4 times a day.

Since the last update we have not found published data on its excretion in breastmilk.

Its wide volume of distribution and short half-life make it unlikely it will transfer into breastmilk in significant amounts.

Carbidopa increases prolactin levels (Masturzo 1979, Brown 1976) and inhibits the suppressive effects of levodopa on prolactin (Camanni 1978).


See below the information of this related product:

  • Levodopa (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

We do not have alternatives for Carbidopa.

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Carbidopa is also known as


Carbidopa in other languages or writings:

Group

Carbidopa belongs to this group or family:

Tradenames

Main tradenames from several countries containing Carbidopa in its composition:

  • Carlevod™. Contains other elements than Carbidopa in its composition
  • Cloison™. Contains other elements than Carbidopa in its composition
  • Credanil™. Contains other elements than Carbidopa in its composition
  • Duodopa™. Contains other elements than Carbidopa in its composition
  • Lebocar™. Contains other elements than Carbidopa in its composition
  • Lecarge™. Contains other elements than Carbidopa in its composition
  • Lodosyn
  • Nakom™. Contains other elements than Carbidopa in its composition
  • Nervocur™. Contains other elements than Carbidopa in its composition
  • Parkinel™. Contains other elements than Carbidopa in its composition
  • Prikap™. Contains other elements than Carbidopa in its composition
  • Racovel™. Contains other elements than Carbidopa in its composition
  • Sinemet™. Contains other elements than Carbidopa in its composition
  • Ternovag™. Contains other elements than Carbidopa in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 58 %
Molecular weight 244 daltons
Protein Binding 76 %
VD 3,6 l/Kg
pKa 5,66 -
Tmax 2,4 hours
T1/2 1,8 hours

References

  1. Merck. Levodopa/Carbidopa (Sinemet). Drug Summary. 2018 Full text (in our servers)
  2. AEMPS - MSD. Levodopa/Carbidopa (Sinemet). Ficha técnica. 2017 Full text (in our servers)
  3. Masturzo P, Murialdo G, Carolei A, Polleri A. Effects of the inhibition of aromatic aminoacids decarboxylase on prolactin secretion in humans. Boll Soc Ital Biol Sper. 1979 Feb 28;55(4):366-72. Abstract
  4. Camanni F, Picotti GB, Massara F, Molinatti GM, Mantegazza P, Müller EE. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients. J Clin Endocrinol Metab. 1978 Sep;47(3):647-52. Abstract
  5. Brown GM, Garfinkel PE, Warsh JJ, Stancer HC. Effect of carbidopa on prolactin, growth hormone and cortisol secretion in man. J Clin Endocrinol Metab. 1976 Jul;43(1):236-9. Abstract

Total visits

2,692

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM